[go: up one dir, main page]

MX2020012964A - Metodos para el tratamiento de cancer de vejiga. - Google Patents

Metodos para el tratamiento de cancer de vejiga.

Info

Publication number
MX2020012964A
MX2020012964A MX2020012964A MX2020012964A MX2020012964A MX 2020012964 A MX2020012964 A MX 2020012964A MX 2020012964 A MX2020012964 A MX 2020012964A MX 2020012964 A MX2020012964 A MX 2020012964A MX 2020012964 A MX2020012964 A MX 2020012964A
Authority
MX
Mexico
Prior art keywords
treatment
methods
bladder cancer
bladder
cancer
Prior art date
Application number
MX2020012964A
Other languages
English (en)
Inventor
Kuan-Chun Huang
Frank Fang
Atsushi Endo
Hyeong-Wook Choi
Xingfeng Bao
Ming-Hong Hao
Dae-Shik Kim
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of MX2020012964A publication Critical patent/MX2020012964A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

En la presente se proporcionan métodos para el tratamiento de cáncer de vejiga.
MX2020012964A 2018-06-01 2019-05-31 Metodos para el tratamiento de cancer de vejiga. MX2020012964A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862679495P 2018-06-01 2018-06-01
US201962826347P 2019-03-29 2019-03-29
PCT/US2019/034933 WO2019232392A1 (en) 2018-06-01 2019-05-31 Methods for the treatment of bladder cancer

Publications (1)

Publication Number Publication Date
MX2020012964A true MX2020012964A (es) 2021-02-16

Family

ID=67138025

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020012964A MX2020012964A (es) 2018-06-01 2019-05-31 Metodos para el tratamiento de cancer de vejiga.

Country Status (11)

Country Link
US (1) US12251394B2 (es)
EP (1) EP3801561B1 (es)
JP (1) JP7335277B2 (es)
KR (1) KR20210015937A (es)
CN (1) CN112512531B (es)
AU (1) AU2019277679B2 (es)
BR (1) BR112020024605A2 (es)
CA (1) CA3101623A1 (es)
MX (1) MX2020012964A (es)
SG (1) SG11202011434SA (es)
WO (1) WO2019232392A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230141284A1 (en) 2020-04-10 2023-05-11 Ono Pharmaceutical Co., Ltd. Cancer therapeutic method
EP4398901A1 (en) 2021-09-09 2024-07-17 Eisai R&D Management Co., Ltd. Biomarkers for sting agonists and methods of using the same

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2257704B (en) 1991-07-18 1995-03-01 Erba Carlo Spa Cyclic oligonucleotides phosphorothioates
WO2005087238A2 (en) 2004-03-15 2005-09-22 Karaolis David K R Method for stimulating the immune, inflammatory or neuroprotective response
US7592326B2 (en) 2004-03-15 2009-09-22 Karaolis David K R Method for stimulating the immune, inflammatory or neuroprotective response
US8076303B2 (en) 2005-12-13 2011-12-13 Spring Bank Pharmaceuticals, Inc. Nucleotide and oligonucleotide prodrugs
WO2009133560A1 (en) 2008-04-29 2009-11-05 Smart Assays Non-hydrolyzable and permeable cyclic bis-[nucleotide monophosphate] derivatives and uses thereof
CN102199183B (zh) 2010-03-26 2013-12-18 北京大学 环二鸟苷酸及其类似物和制备方法
JP6333843B2 (ja) 2012-12-13 2018-05-30 アデュロ バイオテック，インコーポレイテッド 明確な立体化学を有する環状プリンジヌクレオチドを含む組成物ならびにそれらの調製および使用方法
EP2992000B1 (en) 2013-05-03 2020-07-08 The Regents of The University of California Cyclic di-nucleotide induction of type i interferon
US9549944B2 (en) 2013-05-18 2017-01-24 Aduro Biotech, Inc. Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
MX354057B (es) 2013-05-18 2018-02-09 The Regents Of The Univ Of California Star Composiciones y métodos para activar la señalización dependiente del "estimulador del gene de interferón".
JP2016538344A (ja) 2013-11-19 2016-12-08 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ 癌処置としてのｓｔｉｎｇアゴニストの使用
EP3071229A4 (en) 2013-11-22 2017-05-10 Brock University Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants
ES2692226T3 (es) 2014-06-04 2018-11-30 Glaxosmithkline Intellectual Property Development Limited Dinucleótidos cíclicos como moduladores de STING
WO2016096174A1 (en) 2014-12-16 2016-06-23 Invivogen Fluorinated cyclic dinucleotides for cytokine induction
CN107106589A (zh) 2014-12-17 2017-08-29 立博美华基因科技有限责任公司 用cGAMP或cGAsMP治疗癌症的方法
GB201501462D0 (en) * 2015-01-29 2015-03-18 Glaxosmithkline Ip Dev Ltd Novel compounds
JP6692826B2 (ja) 2015-03-10 2020-05-13 アドゥロ バイオテック，インク． 「インターフェロン遺伝子刺激因子」依存性シグナル伝達の活性化のための組成物及び方法
UA123701C2 (uk) 2015-08-13 2021-05-19 Мерк Шарп І Доум Корп. Циклічні динуклеотидні сполуки як агоністи sting
KR20180066241A (ko) 2015-10-28 2018-06-18 아두로 바이오테크, 인코포레이티드 “인터페론 유전자의 자극제”-의존성 신호전달을 활성화시키기 위한 조성물 및 방법
TWI704154B (zh) 2015-12-03 2020-09-11 英商葛蘭素史克智慧財產發展有限公司 新穎化合物
WO2017123657A1 (en) 2016-01-11 2017-07-20 Gary Glick Cyclic dinucleotides for treating conditions associated with sting activity such as cancer
CA3019628A1 (en) 2016-04-07 2017-10-12 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators
JOP20170188A1 (ar) 2016-11-25 2019-01-30 Janssen Biotech Inc ثنائي النوكليوتيدات الحلقية كمنبهات ستينغ (sting)
US20190336615A1 (en) 2017-01-27 2019-11-07 Silverback Therapeutics, Inc. Tumor targeting conjugates and methods of use thereof
US20200055883A1 (en) * 2017-02-17 2020-02-20 Eisai R&D Management Co., Ltd. Cyclic di-nucleotides derivative for the treatment of cancer
WO2018198084A1 (en) 2017-04-27 2018-11-01 Lupin Limited Cyclic di-nucleotide compounds with tricyclic nucleobases
AR113224A1 (es) * 2017-04-28 2020-02-19 Novartis Ag Conjugados de anticuerpo que comprenden un agonista de sting
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
WO2019043634A2 (en) 2017-08-30 2019-03-07 Beijing Xuanyi Pharmasciences Co., Ltd. CYCLIC DI-NUCLEOTIDES AS STIMULATORS OF INTERFERON GENE MODULATORS
US10947263B2 (en) 2017-08-31 2021-03-16 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
CN111032672B (zh) 2017-08-31 2024-09-13 百时美施贵宝公司 作为抗癌剂的环二核苷酸
US10953032B2 (en) 2017-08-31 2021-03-23 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
WO2019046511A1 (en) 2017-08-31 2019-03-07 Sperovie Biosciences, Inc. COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE

Also Published As

Publication number Publication date
US20210205348A1 (en) 2021-07-08
JP2021525758A (ja) 2021-09-27
CN112512531B (zh) 2024-04-09
CA3101623A1 (en) 2019-12-05
EP3801561B1 (en) 2025-03-19
US12251394B2 (en) 2025-03-18
EP3801561A1 (en) 2021-04-14
CN112512531A (zh) 2021-03-16
AU2019277679A1 (en) 2020-12-24
BR112020024605A2 (pt) 2021-04-06
JP7335277B2 (ja) 2023-08-29
SG11202011434SA (en) 2020-12-30
KR20210015937A (ko) 2021-02-10
AU2019277679B2 (en) 2024-11-28
WO2019232392A1 (en) 2019-12-05

Similar Documents

Publication Publication Date Title
CL2019002304A1 (es) Compuestos para el tratamiento del cáncer.
CL2019002461A1 (es) Arn terapéutico.
ECSP17073743A (es) Moduladores de k-ras
CL2018003123A1 (es) Terapia de combinación para el tratamiento del cáncer
CO2020016619A2 (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso
CL2018001512A1 (es) Anticuerpos anti-cd73 humanizados.
CL2019001874A1 (es) Inhibidores de tgfß1 isoforma-específicos contexto-permisivos y uso de los mismos.
CO2018008761A2 (es) Derivados de maitansinoide, conjugados de los mismos métodos de uso
CL2019001554S1 (es) Automóvil.
CO2021017845A2 (es) Proteínas multiespecíficas
CO2017004736A2 (es) Péptidos macrociclicos útiles como inmunomoduladores
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
DK3740504T5 (da) CD70 kombinationsterapi
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
CL2018003443A1 (es) Tratamientos para el cancer.
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CL2015002571A1 (es) Composiciones y métodos para le diagnostico y tratamiento del cáncer hepático.
EA201991818A1 (ru) Лечение рака
MX2018010993A (es) Derivados de icariina e icaritina.
MX2022007801A (es) Formas polimorficas de rad1901-2hcl.
DK3768830T5 (da) Cancerterapi
MX2022007955A (es) Regimenes de dosificacion de erdafitinib.
UY36286A (es) Tratamientos médicos basados en anamorelina
IL281845A (en) Combination therapy for the treatment of cancer
IL281600A (en) Methods of treating cancer